Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;13(9):1489-1495.
doi: 10.1111/jdi.13829. Epub 2022 May 26.

Combination of anti-CD25 antibody and poly I:C treatment in pregnant NOD mice may be used as 'pregnancy-related' type 1 diabetes model

Affiliations

Combination of anti-CD25 antibody and poly I:C treatment in pregnant NOD mice may be used as 'pregnancy-related' type 1 diabetes model

Akira Shimada et al. J Diabetes Investig. 2022 Sep.

Abstract

Aims/introduction: Some women develop type 1 diabetes during pregnancy or immediately after delivery. However, the underlying pathophysiology remains largely unknown, probably because of the lack of a suitable animal model. In this study, we administered pregnant NOD mice with an anti-CD25 antibody to reduce regulatory T cells along with poly I:C and examined the onset of diabetes.

Materials and methods: Anti-CD25 antibody and poly I:C were intraperitoneally administered to mated female NOD mice. Mice delivered within 3 weeks after the treatment, and the onset of diabetes during pregnancy or within 6 weeks after delivery was examined. Some mice were killed 1 week after treatment, and their spleen and pancreas were excised to examine the expression levels of cytokines and for histological examination.

Results: Half of the mice treated with anti-CD25 antibody plus poly I:C developed diabetes, as compared with none of the poly I:C-injected mice (P < 0.05). The ratios of interleukin-18/forkhead box P3 and granzyme B/forkhead box P3 were higher in the pancreas of anti-CD25 antibody plus poly I:C-treated mice than in the pancreas of control mice. The insulitis score decreased in the pancreas of anti-CD25 antibody plus poly I:C-injected pregnant NOD mice.

Conclusions: We describe the use of anti-CD25 antibody to reduce regulatory T cells and poly I:C as a Toll-like receptor 3 stimulator to mimic viral infection in a pregnant NOD mouse, which can be used as a model of 'pregnancy-related' type 1 diabetes.

Keywords: NOD mouse; Pregnancy; Type 1 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diabetes incidence in treated pregnant NOD mice. Solid line: anti‐CD25 antibody + poly I:C injection group (n = 14); dotted line: poly I:C‐only injection group (n = 9). *P < 0.05. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
Interleukin (IL)‐18/forkhead box P3 (Foxp3) and granzyme B/Foxp3 ratios in the pancreas of treated pregnant NOD mice. Closed bar: anti‐CD25 antibody + poly I:C injection group (n = 5); open bar: poly I:C only injection group (n = 5). *P < 0.05.
Figure 3
Figure 3
Lower insulitis score observed in the pancreas of anti‐CD25 antibody plus poly I:C‐injected pregnant NOD mice. *P < 0.05.

References

    1. Shimizu I, Makino H, Osawa H, et al. Association of fulminant type 1 diabetes with pregnancy. Diabetes Res Clin Pract 2003; 62: 33–38. - PubMed
    1. Tada A, Shimada A, Yamada T, et al. A mimic of viral double‐stranded RNA triggers fulminant type 1 diabetes‐like syndrome in regulatory T cell‐deficient autoimmune diabetic mouse. J Immunol 2011; 187: 4947–4953. - PubMed
    1. Fukushima K, Abiru N, Nagayama Y, et al. Combined insulin B:9‐23 self‐peptide and polyinosinic‐polycytidylic acid accelerate insulitis but inhibit development of diabetes by increasing the proportion of CD4+Foxp3+ regulatory T cells in the islets in non‐obese diabetic mice. Biochem Biophys Res Commun 2008; 367: 719–724. - PubMed
    1. Ellis JS, Wan X, Braley‐Mullen H. Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild‐type and B‐cell‐deficient NOD mice. Immunology 2013; 139: 179–186. - PMC - PubMed
    1. Oikawa Y, Shimada A, Kasuga A, et al. Systemic administration of IL‐18 promotes diabetes development in young nonobese diabetic mice. J Immunol 2003; 171: 5865–5875. - PubMed

Grants and funding